Progression of Macular Atrophy in Patients Receiving Long-Term Anti-VEGF Therapy for Age-Related Macular Degeneration: Real-Life Data
Ophthalmologica · 2022 · 245 (2) · 152-160
DOI: 10.1159/000520595 ↗Kurz gefasst
Fachartikel in der Zeitschrift Ophthalmologica, online erschienen am 24.11.2021. Verfasst von Styliani Blazaki und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, University Ηospital of Heraklion, Heraklion, Greece. Hauptthemen laut MEDLINE: Angiogenesis Inhibitors, Wet Macular Degeneration. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 13 Literaturangaben.
Abstract (Originalsprache)
Purpose
This study aimed to evaluate the progression of macular atrophy (MA) based on near-infrared reflectance (NIR) and optical coherence tomography (OCT) images, in patients with age-related macular degeneration (AMD), receiving anti-vascular endothelial growth factor (anti-VEGF) treatment for at least a 6-year period. Materials and Methods: This retrospective study included 53 naïve patients (53 eyes) with neovascular AMD from 2 centers, who were treated with anti-VEGF intravitreal injections and had no MA at baseline. MA was evaluated in an annual basis using NIR images, while all available OCT images were used to confirm that the atrophic area fulfilled the criteria proposed by the Classification of Atrophy Meetings (CAM) group for complete retinal pigment epithelium and outer retinal atrophy. Incidence and progression of MA were evaluated. Associations with best-corrected visual acuity (BCVA) and total number of injections were also studied.
Results
Treatment duration of our patients was 7.34 ± 1.54 years. The mean number of anti-VEGF injections was 24.4 ± 13.6. BCVA at baseline was 0.38 ± 0.27 logMAR, while at the final visit, it was 0.60 ± 0.35 logMAR (p = 0.731). The cumulative incidence of new MA at years 1, 2, 3, 4, 5, and 6 was 1.89%, 18.87%, 32.08%, 39.62%, 49.06%, and 50.94%, respectively. In patients who developed MA, mean MA area increased from zero at baseline to 5.66 ± 7.18 mm2 at the final visit. The estimated annual enlargement of MA was 0.45 mm/year based on square root transformation (1.12 mm2/year, untransformed data). MA progression does not appear to be significantly associated with age (R = 0.055; p = 0.784), gender (R = 0.113; p = 0.576), BCVA (R = 0.168; p = 0.404), and total number of injections (R = 0.133; p = 0.255).
Conclusion
In this real-life setting, half of the neovascular AMD patients under anti-VEGF treatment, without MA at therapy initiation, developed MA over a period of at least 6 years. In this work, the number of injections did not seem to have a significant association with MA progression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, University Ηospital of Heraklion, Heraklion, Greece.
- Department of Ophthalmology, Korgialenio-Benakio General Hospital, Athens, Greece.
- Biostatistics Laboratory, Faculty of Medicine, University of Crete, Heraklion, Greece.
Zitieren
APA
Blazaki, S., Blavakis, E., Smoustopoulos, G., Bontzos, G., Stavrakakis, A., Chlouverakis, G., Kabanarou, S., Xirou, T., & Tsilimbaris, M. (2022). Progression of Macular Atrophy in Patients Receiving Long-Term Anti-VEGF Therapy for Age-Related Macular Degeneration: Real-Life Data. Ophthalmologica, 245(2), 152-160. https://doi.org/10.1159/000520595
Vancouver
Blazaki S, Blavakis E, Smoustopoulos G, Bontzos G, Stavrakakis A, Chlouverakis G, et al. Progression of Macular Atrophy in Patients Receiving Long-Term Anti-VEGF Therapy for Age-Related Macular Degeneration: Real-Life Data. Ophthalmologica. 2022;245(2):152-160. doi:10.1159/000520595
BibTeX
@article{Blazaki2022,
author = {Blazaki, Styliani and Blavakis, Emmanouil and Smoustopoulos, Georgios and Bontzos, Georgios and Stavrakakis, Anastasios and Chlouverakis, Gregory and Kabanarou, Stamatina and Xirou, Tina and Tsilimbaris, Miltiadis},
title = {Progression of Macular Atrophy in Patients Receiving Long-Term Anti-VEGF Therapy for Age-Related Macular Degeneration: Real-Life Data},
journal = {Ophthalmologica},
year = {2022},
volume = {245},
number = {2},
pages = {152--160},
doi = {10.1159/000520595}
}
EUVIMED